Retatrutide for PCOS: Off-Label Use, Evidence, Risks, and What Patients Need to Know

What Is Retatrutide and Why Is It Being Discussed for PCOS?

Retatrutide is a single peptide that simultaneously activates three receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and the glucagon receptor. Eli Lilly is developing it under the investigational name LY3437943. No regulatory agency has approved it for any indication as of July 2025.

Interest in retatrutide for PCOS stems from the biology: PCOS is driven in part by insulin resistance, compensatory hyperinsulinemia, androgen excess, and weight gain that worsens all three. A drug that reduces body weight by roughly 24% and improves insulin sensitivity addresses the upstream drivers of the syndrome rather than only its symptoms.

How the Triple Agonist Mechanism Differs From Semaglutide or Tirzepatide

Semaglutide (Ozempic, Wegovy) targets only GLP-1 receptors. Tirzepatide (Mounjaro, Zepbound) adds GIP agonism. Retatrutide adds glucagon receptor agonism on top of both, which increases hepatic glucose output suppression and resting energy expenditure beyond what dual agonism achieves [1]. That third receptor is the main reason Phase 2 data showed weight loss exceeding any previously published incretin agent at comparable timepoints.

The PCOS Problem Retatrutide Targets

The Endocrine Society's 2023 clinical practice guideline on PCOS states that lifestyle-based weight reduction of 5 to 10% can meaningfully improve menstrual regularity, lower free androgen index, and restore spontaneous ovulation in overweight patients [2]. Retatrutide's weight-loss magnitude exceeds that threshold substantially, which is the primary biological rationale for its off-label use in this population.

Current FDA Status and What "Off-Label" Means Here

Retatrutide has no approved indication. Physicians in the United States may legally prescribe any approved drug off-label, but retatrutide is not yet approved for anything. That places it in a more restricted category: patients can access it only through a clinical trial, a compassionate-use (expanded access) request under 21 CFR Part 312.310, or through compounding pharmacies that obtain the API from an unregulated source [3].

Compounding and Gray-Market Access

Some compounding pharmacies have begun offering retatrutide peptide. The FDA has not listed retatrutide on any shortage list that would legally permit 503A or 503B compounders to copy a branded product. Any compounded retatrutide therefore carries additional uncertainty about purity, potency, and sterility beyond the already-limited efficacy data in PCOS. The FDA's guidance on compounding of drug products not on the shortage list is explicit that such compounding does not meet the standard exemptions [4].

What Patients Should Understand Before Requesting It

A clinician prescribing or facilitating access to retatrutide for PCOS should document informed consent that covers: the absence of FDA approval, the Phase 2-only evidence base for any indication, the unknown long-term safety profile, and the availability of approved alternatives. The American Society for Reproductive Medicine advises that when evidence is limited, the informed-consent process itself becomes a clinical safeguard [5].

Phase 2 Evidence: What the Data Actually Show

The foundational Phase 2 trial (NCT04881760) randomized 338 adults with obesity (BMI <27 not eligible) to retatrutide doses from 1 mg to 24 mg weekly or placebo for 24 weeks, with a 24-week extension arm reaching 48 weeks total [6]. Participants were adults with obesity or overweight plus at least one weight-related comorbidity; PCOS was not a prespecified subgroup.

Primary Weight-Loss Findings

At 24 weeks, the 12 mg dose group lost a mean 17.5% of body weight versus 1.6% for placebo (P<0.001) [6]. The 24 mg group, followed to 48 weeks, reached 24.2% mean body-weight reduction. No approved anti-obesity medication has matched that figure in a head-to-head comparison at the same timepoint.

For context: STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo [7]. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 22.5% weight loss at 72 weeks [8]. Retatrutide's 48-week figure exceeds both, though direct comparison across trials is limited by different populations and follow-up durations.

Metabolic Markers Relevant to PCOS

In the Phase 2 trial, retatrutide produced statistically significant reductions in fasting insulin, HOMA-IR (a validated insulin-resistance index), triglycerides, and waist circumference compared with placebo [6]. These are all mechanisms through which weight-loss drugs may reduce androgen production in PCOS: lower insulin means lower LH-driven theca cell androstenedione output. No testosterone or SHBG measurements were reported in the published Phase 2 data because PCOS was not studied.

What Is Missing From the Evidence Base

There are no published randomized controlled trials of retatrutide in women with PCOS. There are no published data on: menstrual cycle regularity as an outcome, ovulation rates, free androgen index changes, anti-Müllerian hormone levels, or fertility outcomes under retatrutide. The GRADE rating for using retatrutide in PCOS is therefore Level C: the recommendation rests on biological plausibility and extrapolation from obesity trial data, not direct evidence [9].

Biological Rationale: Why Clinicians Think It Could Help

PCOS involves a cycle in which insulin resistance drives hyperinsulinemia, hyperinsulinemia amplifies LH signaling in ovarian theca cells, and excess androgen production results in anovulation, hirsutism, and acne [2]. Weight loss interrupts this cycle at multiple points simultaneously.

Insulin Sensitization and Androgen Reduction

Metformin, which is itself off-label for PCOS in most countries (approved only for type 2 diabetes), reduces free testosterone by approximately 20 to 30% in women with PCOS primarily through insulin sensitization [10]. Retatrutide produces substantially greater HOMA-IR reductions than metformin in overlapping populations, suggesting the androgen-lowering effect could be larger, though no trial has tested that hypothesis directly.

GLP-1 Receptor Effects on Ovarian Function

GLP-1 receptors are expressed in human granulosa cells and ovarian tissue [11]. GLP-1 agonism has been shown in small studies to improve oocyte quality markers and reduce ovarian volume independent of weight change [12]. Retatrutide's GLP-1 component may therefore offer direct ovarian benefit beyond what weight loss alone would explain, though this remains speculative without PCOS-specific data.

Glucagon Receptor Agonism: Unique Contribution

The glucagon component raises questions as well as potential benefits. Higher glucagon signaling increases hepatic glucose production acutely, but in the context of a GLP-1-dominant triple agonist, the net effect is increased energy expenditure and enhanced fat oxidation without clinically meaningful hyperglycemia in Phase 2 normoglycemic participants [6]. Whether glucagon receptor agonism has direct effects on ovarian steroidogenesis is unknown.

Risks and Safety Considerations Specific to Women With PCOS

Gastrointestinal Adverse Effects

In the Phase 2 trial, nausea occurred in 42% of participants on the 12 mg dose versus 9% for placebo; vomiting occurred in 20% versus 2% [6]. These rates are higher than published rates for semaglutide 2.4 mg (nausea 44%, vomiting 24% in STEP-1 [7]) at similar timepoints but comparable. Dose titration over 16 to 20 weeks substantially reduces peak GI burden.

Thyroid C-Cell Risk

All GLP-1 receptor agonists carry an FDA boxed warning for thyroid C-cell tumors based on rodent studies showing dose-dependent C-cell hyperplasia and medullary thyroid carcinoma [13]. Retatrutide shares this concern. The boxed warning is a class effect; retatrutide's investigational label carries the same precaution. Women with PCOS who have a personal or family history of MEN2 or medullary thyroid carcinoma should not use any GLP-1 agonist, including retatrutide.

Gallbladder Disease

Rapid weight loss of any cause increases biliary sludge and gallstone formation. In SURMOUNT-1, cholelithiasis occurred in 1.2% of tirzepatide-treated patients versus 0.4% for placebo [8]. Retatrutide's Phase 2 trial was not powered to detect a gallbladder signal, but the biological mechanism applies equally. Baseline gallbladder ultrasound is reasonable before initiating any high-efficacy weight-loss agent.

Reproductive Safety and Contraception

No human or animal reproductive-toxicity data for retatrutide are publicly available as of July 2025. The FDA requires women of reproductive potential enrolled in GLP-1 trials to use reliable contraception throughout treatment and for a washout period afterward. For semaglutide, the FDA recommends stopping treatment at least 2 months before a planned pregnancy [14]. Retatrutide's half-life is approximately 6 days, suggesting a similar or possibly shorter washout would be adequate biologically, but no regulatory guidance exists yet.

This is particularly relevant for PCOS because improved ovulation from weight loss may increase pregnancy risk in women who were previously anovulatory and not using contraception. Clinicians should counsel patients that successful treatment may restore fertility before they expect it.

Bone and Lean-Mass Considerations

Rapid weight loss from any agent reduces both fat mass and lean mass. Retatrutide's Phase 2 data showed approximately 40% of weight lost was lean tissue at the highest doses, which is within the range seen with semaglutide [6]. Women with PCOS already have altered bone turnover markers compared to controls [15]. Resistance exercise during treatment is the standard clinical strategy to preserve lean mass and should be recommended explicitly, not optionally.

How Retatrutide Compares to Approved and Established Options for PCOS

No drug is FDA-approved specifically for PCOS as a syndrome. Approved and commonly used agents address individual features:

• Metformin (off-label for PCOS): Reduces insulin resistance and free testosterone, improves menstrual regularity; typical dose 1,500 to 2,000 mg/day; weight-neutral to modestly weight-reducing [10].
• Letrozole (off-label for ovulation induction): The American Society for Reproductive Medicine designates letrozole as first-line for ovulation induction in PCOS; it does not address insulin resistance or androgen excess broadly [5].
• Spironolactone (off-label for hyperandrogenism): 50 to 200 mg/day reduces hirsutism and acne by blocking androgen receptors; it does not improve metabolic features [2].
• Clomiphene: FDA-approved for ovulatory dysfunction; lower live-birth rates than letrozole in PCOS per NEJM data (N=750, live-birth rate 19.1% vs. 27.5% for letrozole) [16].
• Semaglutide 2.4 mg (Wegovy): FDA-approved for obesity; produces 14.9% weight loss; GLP-1 agonism may benefit PCOS directly; longer safety record than retatrutide [7].
• Tirzepatide 15 mg (Zepbound): FDA-approved for obesity; produces up to 22.5% weight loss; dual agonist with a more developed safety database than retatrutide [8].

A practical point: tirzepatide achieves weight loss in the 20 to 22% range with two years of published Phase 3 safety data, while retatrutide exceeds it modestly but has only 48 weeks of Phase 2 data and no approval. For most PCOS patients, tirzepatide represents a more defensible choice at this time.

Monitoring Protocol for Clinicians Who Proceed With Off-Label Retatrutide

If a physician and patient decide, after full informed consent, to proceed with retatrutide for PCOS through a legitimate access pathway, the following monitoring framework is clinically reasonable based on analogous GLP-1 agonist protocols from the Endocrine Society's obesity pharmacotherapy guidelines [17]:

Baseline Assessment

Order fasting glucose, HbA1c, fasting insulin, HOMA-IR, lipid panel, LFTs, TSH, free testosterone, SHBG, free androgen index, anti-Müllerian hormone, and pelvic ultrasound. Document weight, BMI, waist circumference, blood pressure, and menstrual history. Confirm no personal or family history of MEN2 or medullary thyroid carcinoma.

Follow-Up Schedule

• Weeks 4, 8, 12: Weight, blood pressure, GI symptom assessment, dose-titration decision.
• Month 3: Fasting glucose, fasting insulin, HOMA-IR, LFTs.
• Month 6: Full metabolic panel plus free testosterone, SHBG, free androgen index, menstrual cycle diary review, and pregnancy test if indicated.
• Month 12: Repeat full baseline labs, repeat pelvic ultrasound, reassess benefit-risk balance.

Stopping Criteria

Discontinue retatrutide and refer to endocrinology or gastroenterology if: serum lipase exceeds three times the upper limit of normal, ALT exceeds three times the upper limit of normal, symptomatic gallstones develop, a neck mass or hoarseness suggests thyroid pathology, or the patient becomes pregnant.

What the Phase 3 Pipeline May Eventually Tell Us

Eli Lilly's TRIUMPH program includes Phase 3 trials of retatrutide in obesity (NCT05929066) and type 2 diabetes. None of the registered Phase 3 trials as of July 2025 specifically study PCOS as a primary or secondary endpoint [18]. Exploratory endpoints in the obesity trials may capture menstrual regularity or reproductive hormones in female subgroups, but that data would represent subgroup analysis rather than a prespecified PCOS study.

Researchers at several academic centers have called for a dedicated PCOS-focused trial of retatrutide, pointing to the unmet need: PCOS affects approximately 8 to 13% of reproductive-age women globally according to the World Health Organization, yet no drug is approved for the full syndrome [19]. A dedicated 52-week RCT measuring ovulation rate, free androgen index, and quality-of-life outcomes alongside weight change would move retatrutide from GRADE C to GRADE A or B evidence in this population.